Skip to Content

Boston Scientific Corp BSX Stock Quote

| Rating as of

NYSE:BSX

Morningstar‘s Stock Analysis BSX

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Boston Scientific Enjoys Strong Revenue Growth in Q3, but Higher Costs Still Dog the Firm

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Boston Scientific delivered robust revenue growth in the third quarter but fell short of FactSet consensus expectations on the bottom line thanks to continued pressure on materials and freight costs. Nonetheless, the firm remains on track to meet our full-year expectations, and we’re holding steady on our $45 fair value estimate. We’re pleased to see Boston make progress with the development of its pipeline and commercialization of key products, including Watchman for left atrial appendage closure and Farapulse for safer atrial fibrillation ablation—progress that reinforces Boston’s narrow economic moat, in our view.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BSX

Company Profile BSX

Business Description

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Contact
300 Boston Scientific Way
Marlborough, MA, 01752-1234
T +1 508 683-4000
Industry Medical Devices
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2021
Employees 41,000

Related News BSX